AGPAT family members act as potential predictive biomarkers and therapeutic targets in cervical cancer
Nannan Gui, Hanyi Pan, Weijuan Lu, Guiqiong Pan, Xiaoyu Zhou, Yuzhen Chen, Mingyang Jin, Changyong Yang, Mingyou Dong, Yuexiu Liang · 2026
Read AGPAT family members act as potential predictive biomarkers and therapeutic targets in cervical cancer by Nannan Gui, Hanyi Pan, Weijuan Lu, Guiqiong Pan, Xiaoyu Zhou, Yuzhen Chen, Mingyang Jin, Changyong Yang, Mingyou Dong, Yuexiu Liang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13473034.txt.
Description
Gui and co-authors screened the AGPAT enzyme family, five fat-building enzymes, for biomarker value in cervical cancer using cancer atlas data and two independent validation datasets. Their 2026 study analyzed 306 cervical cancer patients, supplementing the atlas's three normal samples with ten healthy cervix samples from another database.
AGPAT4 stood out as significantly altered in tumors, and high expression of AGPAT3 and AGPAT4 each predicted worse survival for patients. The team folded AGPAT3 and AGPAT4 levels together with tumor stage, node stage, and clinical stage into a nomogram forecasting one-, three-, and five-year survival. Laboratory validation in clinical samples backed the computational signal, though the authors concede animal studies are still needed to prove AGPAT3's role directly.
Catalog record
| CREATOR | Nannan Gui, Hanyi Pan, Weijuan Lu, Guiqiong Pan, Xiaoyu Zhou, Yuzhen Chen, Mingyang Jin, Changyong Yang, Mingyou Dong, Yuexiu Liang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 65 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |